Global Perspectives

The European Commission and Medicines Agency seem to be moving in advance of their ICH partners to update standards.

Tiered pricing is used throughout industry to help increase affordability and access to drugs in the developing world.

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

Merck and AstraZeneca Tackle Cervical Cancer and Tuberculosis.

There has been increasing cooperation between the EMA and the FDA in recent years, and this looks set to continue in the future.

Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.

A look at MVI's malaria work in developing countries.

The early part of the decade saw a decline in vaccine sales and manufacture, but finally the industry is bouncing back, with Europe particularly well placed to make an impact.

A look at why Brazil revised its GMP standards and how the changes will affect the local pharmaceutical industry.

Manufacturers and regulators on both sides of the ocean move to ensure the safety of heparin and other globally distributed drug products.

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

Europe moves to place excipient GMP and GDP standards on the same level as active pharmaceutical ingredients.

Despite being a historically strong performer in the pharmaceutical arena, Germany is now underperforming compared with the growth of other European markets.

The growth of Brazil's generic-drug market is on a fast track, but what are the projections for the sector's future?

As demand for global vaccine development and production grows, all eyes are turning to Asia.

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Regulators and industry move to require inspections of API manufacturing facilities.

The end of 2009 is creeping closer and analysts are already looking towards 2010 and wondering what new challenges are in store for the pharma industry.

New pricing controls and healthcare reforms may be pushing the pharmaceutical market out of this southeast Asian country. This article contains bonus online-exclusive material.

Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.

Designated as a "pharmerging market," Brazil is revamping its pricing models.

Jones explains how to save UK pharma.

China's State Food and Drug Administration has completed a new draft of GMP guidelines, but after a series of quality-control events, it will take time for the country to regain the global pharmaceutical industry's trust.

Patent infringement claims and a lack of clear global trade distribution routes may be unraveling the country's generic-drug export industry.

Despite its shrinking domestic economy, Ireland is determined not to let its pharmaceutical industry fade into the shadow of global recession.

The Japanese government is eager to jumpstart its generic-drug market, but changes must come first.

Although industry is tightening its belt, contract manufacturers across Europe are actually making out quite well by taking on additional projects and new roles.

Scientists studying epilepsy have traditionally focused on the comings and goings of ions through molecular channels in nerve cells, and many current antiseizure therapies seek to modulate that dynamic.

With the economy down and multinational firms capitalizing on patents in developing countries, India's R&D sector still has a long way to grow.

The Romanian pharmacetuical market has grown significantly in recent years, but with stagnation on the horizon, a path forward is needed.